ساخت اکانت کاربری رایگان

مقالات پذیرفته شده کنگره

  • صفحه نخست
  • مقالات پذیرفته شده اولین کنگره بین المللی ژنتیک سرطان
بازنشر

  • Role of Antihistamines in Modulating Drug Resistance in Colorectal Cancer

  • Mehrnaz Asayesh,1,* Melika Asayesh,2
    1. Student Research Committee, Department of Medical Immunology, Medical Sciences Faculty, Golestan University of Medical Science, Gorgan, Iran.
    2. Student Research Committee, Hamadan University of Medical Science, Hamadan, Iran.


  • Introduction: Colorectal cancer (CRC) is a major global health burden, with nearly 1.9 million new cases reported worldwide in 2022. 5-Fluorouracil (5-FU) remains a cornerstone of CRC chemotherapy and is widely used in treatment regimens such as FOLFOX and FOLFIRI, particularly for advanced and metastatic disease. Despite advances in diagnosis and treatment, therapeutic resistance remains a major challenge in CRC and substantially limits treatment efficacy. However, resistance to 5-FU is a complex and multifactorial process involving diverse molecular and cellular mechanisms. The histaminergic system has emerged as a potential regulator of tumor progression and therapeutic response. In the tumor microenvironment of CRC, histamine can be released by immune cells, including mast cells and eosinophils. Histamine exerts its biological effects through four G protein-coupled receptors (H1R–H4R). Histamine signaling through these receptors has been associated with various processes involved in tumor progression and therapeutic response, including cell proliferation, migration, inflammation, and angiogenesis. Antihistamine drugs, by blocking histamine receptors, may modulate these signaling pathways and potentially influence tumor cell survival and response to anticancer therapies. Therefore, in this study, we evaluated the potential role of antihistamines in modulating drug resistance in colorectal cancer.
  • Methods: A comprehensive search was performed from 2020 to 2026 across PubMed, Scopus, and Web of Science. The keywords included "colorectal cancer", "antihistamines", "drug resistance", and "5-fluorouracil". The search was designed to be highly sensitive, with no restrictions on study design or publication type.
  • Results: It has been demonstrated that histamine signaling influences tumor progression and therapeutic responses in colorectal cancer by modulating inflammatory pathways, immune cell activity, and tumor cell survival. Studies have also shown that antihistamines and histamine receptor antagonists, including cimetidine and ranitidine, may modulate tumor-related signaling pathways and enhance the response to anticancer treatments. Emerging evidence suggests that these agents may influence mechanisms associated with chemotherapy resistance, including pathways involved in cell survival, proliferation, and inflammatory signaling, and may potentially improve the response to 5-fluorouracil (5-FU) based therapy. Hereupon, this review highlights the potential role of antihistamines in modulating histamine-mediated pathways and therapeutic resistance, supporting their possible use as adjunctive strategies in colorectal cancer therapy.
  • Conclusion: This review emphasizes histamine signaling as a potential modulator of drug resistance in colorectal cancer, highlighting antihistamines as a promising approach to influence therapeutic responses and potentially overcome resistance to anticancer treatments. We integrate mechanistic evidence on histamine signaling with emerging evidence on antihistamine-mediated modulation of therapeutic resistance and their potential role in improving responses to 5-fluorouracil-based therapy in colorectal cancer.
  • Keywords: colorectal cancer, antihistamines, drug resistance, 5-fluorouracil

به خانواده بزرگ کنسر ژنتیکس و ژنومیکس سرطان بپیوندید!

ایجاد حساب کاربری رایگان